Synonyms[]
Antibodies[]
Technical Info[]
Staining Pattern[]
- Nuclear
Expression in Normal Tissues[]
Expression in Neoplastic Entities[]
Benign[]
Intermediate/Uncertain Malignant Potential[]
Malignant[]
- Atypical lipomatous neoplasm (tumor) / Well differentiated liposarcoma
- Dedifferentiated Liposarcoma
- Parosteal osteosarcoma[1]
Expression in Non-Neoplastic Entities[]
Pertinent Negatives[]
This antigen is typically NOT expressed by the following entities:
- Benign lipomatous tumors[2]
Practical Uses / Panels[]
- Can be used with MDM2 to differentiate well differentiated liposarcoma (CDK4+, MDM2+) from benign adipose tumors (CDK4-, MDM2-)[3][2]
- Can be used to distinguish dedifferentiated liposarcoma (CDK4+) from poorly differentiated sarcomas (CDK4-)[3]
Common Pitfalls[]
Related Links/Other Resources[]
References[]
- ↑ Takashi Tsuchiyaa, Ki-ichi Sekineb, Shin-ichi Hinoharab, Takeshi Namikia, c, Tsutomu Noboria, c and Yasuhiko Kaneko. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 Genes and Their Prognostic Implications in Osteosarcoma and Ewing Sarcoma. Cancer Genetics and Cytogenetics. Volume 120, Issue 2, 15 July 2000, Pages 91-98.
- ↑ 2.0 2.1 Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol. 2009 Dec;62(12):1127-35.
- ↑ 3.0 3.1 Am J Surg Pathol. 2005 Oct;29(10):1340-7.